

PROVECTUS BIOPHARMACEUTICALS, INC.  
Form 8-K  
January 24, 2014

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 23, 2014

PROVECTUS BIOPHARMACEUTICALS, INC.  
(Exact name of registrant as specified in charter)

Delaware  
(State or other jurisdiction  
of incorporation)

0-9410  
(Commission  
File Number)

90-0031917  
(IRS Employer  
Identification No.)

7327 Oak Ridge Hwy., Knoxville, Tennessee  
37931  
(Address of Principal Executive Offices)

(866) 594-5999  
(Registrant's Telephone Number, Including Area  
Code)

(Former Name or Former Address, If Changed  
Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item Other Events.

8.01.

On January 23, 2014, Provectus Biopharmaceuticals, Inc. (the "Company") submitted a letter to the editor of TheStreet.com responding to the article "The Obsolescence of Provectus' Skin Cancer Drug Means Current Speculative Run Ends Badly" by Adam Feuerstein, published on TheStreet.com on January 23, 2014. A copy of the Company's letter to the editor is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item Financial Statements and Exhibits.  
9.01.

(d) Exhibits.

See Exhibit Index immediately following signature page.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 23, 2014

PROVECTUS BIOPHARMACEUTICALS, INC.

By: /s/ Peter R.  
Culpepper  
Peter R. Culpepper  
Chief Financial Officer and Chief Operating  
Officer

---

EXHIBIT INDEX

Exhibit Number	Description
99.1	Letter to the Editor